Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMB5U3P)

Drug Name
1,1,1-trifluoroheptadecan-2-one Drug Info
Synonyms
PACOCF3; 1,1,1-trifluoroheptadecan-2-one; 141022-99-3; palmityl trifluoromethyl ketone; Palmitoyl Trifluoromethyl Ketone; CHEMBL99344; 1,1,1-Trifluoro-2-heptadecanone; SR-01000597566; Tocris-1460; AC1L1IOS; AC1Q4I4P; SCHEMBL4653611; Pentadecyl trifluoromethyl ketone; CTK4C2431; C17H31F3O; DTXSID00274441; MAHYXYTYTLCTQD-UHFFFAOYSA-N; MolPort-003-983-793; HMS3649G09; 1,1,1-Trifluoroheptadecen-2-one; HMS3267L18; ZINC8036041; IN1174; BS0141; HSCI1_000022; BDBM50085494; 1974AH; 1,1,1-Trifluoro-2-heptadecanone #; AKOS017343267
Cross-matching ID
PubChem CID
4670
CAS Number
CAS 141022-99-3
TTD Drug ID
D0R3AA

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Porphyrin and chlorophyll metabolism 2.13 0.00e+0 23/43 (53.49%) HMOX1;HEPH;FECH;...
Mineral absorption 1.95 1.43e-2 48/60 (80%) MT2A;MT1H;HMOX1;...
Arachidonic acid metabolism -1.64 4.39e-2 48/61 (78.69%) GPX2;PTGDS;PLA2G5;...
Human cytomegalovirus infection -1.65 4.18e-2 201/225 (89.33%) HRAS;GNAI1;KRAS;...
Fatty acid elongation -1.66 4.14e-2 19/27 (70.37%) TECR;ELOVL4;HSD17B12;...
alpha-Linolenic acid metabolism -1.68 3.39e-2 17/25 (68%) ACOX1;PLA2G5;FADS2;...
Linoleic acid metabolism -1.69 3.56e-2 21/29 (72.41%) PLAAT3;CYP2J2;PLA2G4A;...
B cell receptor signaling pathway -1.73 2.27e-2 71/81 (87.65%) AKT1;BTK;NFATC1;...
Natural killer cell mediated cytotoxicity -1.75 1.80e-2 99/131 (75.57%) NFATC1;ICAM2;HRAS;...
Epithelial cell signaling in Helicobacter pylori infect... -1.76 1.84e-2 62/70 (88.57%) ATP6V1B2;ADAM10;CSK;...
Osteoclast differentiation -1.78 1.53e-2 117/127 (92.13%) LILRB4;LCP2;SIRPG;...
Fc epsilon RI signaling pathway -1.80 1.37e-2 57/68 (83.82%) FCER1A;LCP2;MAPK10;...
Herpes simplex virus 1 infection -1.83 1.28e-2 165/498 (33.13%) RNASEL;IFIH1;B2M;...
Graft-versus-host disease -1.84 1.38e-2 32/42 (76.19%) TNF;HLA-DQA1;HLA-DQB1;...
Type I diabetes mellitus -1.89 1.05e-2 38/43 (88.37%) CD86;GAD1;IL1A;...
Cell adhesion molecules -1.91 8.94e-3 118/148 (79.73%) CD86;CNTNAP1;CLDN4;...
Leishmaniasis -1.93 9.94e-3 67/77 (87.01%) HLA-DPA1;NCF2;FCGR2A;...
Epstein-Barr virus infection -1.96 9.58e-3 189/202 (93.56%) TRAF5;IRF9;PSMD13;...
Human immunodeficiency virus 1 infection -1.96 1.10e-2 189/212 (89.15%) TRAF5;PPP3CB;ITPR2;...
Allograft rejection -1.96 1.28e-2 32/38 (84.21%) TNF;HLA-DQA1;HLA-DQB1;...
Viral myocarditis -2.02 7.67e-3 53/60 (88.33%) DAG1;EIF4G3;CD86;...
Steroid biosynthesis -2.05 3.19e-3 19/20 (95%) NSDHL;LSS;CYP24A1;...
Autoimmune thyroid disease -2.15 0.00e+0 46/53 (86.79%) IL5;CD86;TPO;...
Biosynthesis of unsaturated fatty acids -2.16 0.00e+0 21/27 (77.78%) BAAT;ACAA1;FADS1;...
Phagosome -2.51 0.00e+0 118/152 (77.63%) HLA-DPA1;ATP6V1B2;NCF2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H